A phase I/randomised phase II trial of abiraterone acetate with or without RO5503781 in patients with metastatic castration resistant prostate cancer (mCRCP) who have not previously received docetaxel

Trial Profile

A phase I/randomised phase II trial of abiraterone acetate with or without RO5503781 in patients with metastatic castration resistant prostate cancer (mCRCP) who have not previously received docetaxel

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Feb 2016

At a glance

  • Drugs Idasanutlin (Primary) ; Abiraterone; Prednisolone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms MAdCaP
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Nov 2015 Accrual to date is 7% according to United Kingdom Clinical Research Network record.
    • 18 Sep 2015 Accrual to date is 6% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top